Deutsche Bank Starts Regulus Therapeutics (RGLS) at Buy; Analyst Says RG-101 Data Validates Platform
Tweet Send to a Friend
Deutsche Bank initiated coverage on Regulus Therapeutics (NASDAQ: RGLS) with a Buy rating and a price target of $30. Analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
